Cart
sales@molnova.com
1-O-Gentiobiosyl-3,7-dimethoxy-8-hydroxyxanthone
CAS No. 487040-33-5
1-O-Gentiobiosyl-3,7-dimethoxy-8-hydroxyxanthone( ——— )
Catalog No. M38380 CAS No. 487040-33-5
1-O-Gentiobiosyl-3,7-dimethoxy-8-hydroxyxanthone (Compound 18) is a natural product that can be isolated from Swertia mussotii.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name1-O-Gentiobiosyl-3,7-dimethoxy-8-hydroxyxanthone
-
NoteResearch use only, not for human use.
-
Brief Description1-O-Gentiobiosyl-3,7-dimethoxy-8-hydroxyxanthone (Compound 18) is a natural product that can be isolated from Swertia mussotii.
-
Description1-O-Gentiobiosyl-3,7-dimethoxy-8-hydroxyxanthone (Compound 18) is a natural product that can be isolated from Swertia mussotii.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number487040-33-5
-
Formula Weight612.53
-
Molecular FormulaC27H32O16
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
DCZ0415
DCZ0415 induces antimyeloma activity in vitro, in vivo and in primary cells of drug-resistant myeloma patients. DCZ0415 is a potent TRIP13 inhibitor that can impair the repair of non-homologous end junctions and inhibit NF-κB activity.DCZ0415 (10, 20 μM; 72 hours) showed a marked reduction in colony formation, indicating that it inhibited cell proliferation.
-
1-(4-hydroxybenzyl)-...
BChE-IN-11 (compound 10) is a potent, selective and non-competitive BChE (butyrylcholinesterase) inhibitor, with an IC50 of 2.1 μM. BChE-IN-11 can be used for Alzheimer's disease (AD) research.
-
BNTA
BNTA is a potent extracellular matrix (ECM) modulator. In a rat model of arthritis, BNTA modulates arthritis by promoting the synthesis of cartilage structural molecules on chondrocytes through the induction of superoxide dismutase 3 (SOD3) and regulating chondrogenesis through superoxide anion elimination.
